Liuwei Dihuang pills attenuate ovariectomy-induced bone loss by alleviating bone marrow mesenchymal stem cell (BMSC) senescence via the Yes-associated protein (YAP)-autophagy axis.

Bing Liang, Xiongbin Chen, Min Li, Lingling Zhang, Xia Yang, Liangqin Shi, Yanju Gong, Yuanyuan Gong, Huan Xu, Xiao Wu, Zhong Jin, Yanru Wang, Luwei Liu, Xiaohong Yi, Lushuang Xie, Hua Zhong, Chongyang Shen, Yong Wang, Lan Yang

Basic Medicine College, Chengdu University of Traditional Chinese Medicine, Chengdu, China. · pubmed

Paper

Abstract

Liuwei Dihuang pill (LWDH) has been used to treat postmenopausal osteoporosis (PMOP).

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the effects of Liuwei Dihuang pills on bone loss associated with menopause, focusing on the senescence of bone marrow mesenchymal stem cells. While it addresses a condition related to aging (postmenopausal osteoporosis), it primarily deals with symptom management rather than targeting the underlying mechanisms of aging itself. The findings may contribute to the understanding of age-related bone loss but do not significantly advance the broader field of longevity research or lifespan extension. Thus, the impact is rated as a solid but limited contribution.

Author of this paper? Send a correction.